Industry Research Reports
Antibody and Recombinant Protein CDMO- Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
Industry: Medical Care
Published Date: 2025-01-16
Pages: 149 Pages
Report ld: 3460353
Request Sample
Customized Report
- Description
- Table of Contents
- Table of Figures
- Related Reports
PDF Download
- Description
- Table of Contents
- Table of Figures
- Related Reports
- PDF Download
Antibody and Recombinant Protein CDMO Market Size(US$)
CAGR 2025-2031
7%
Market Size,2031
USD 94,330
Million
Market Snapshot
Source: Secondary research, interviews with experts, and QYResearch analysis
The global market for Antibody and Recombinant Protein CDMO was estimated to be worth US$ 59130 million in 2024 and is forecast to a readjusted size of US$ 94330 million by 2031 with a CAGR of 7.0% during the forecast period 2025-2031.
North American market for Antibody and Recombinant Protein CDMO was valued at $ million in 2024 and will reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Antibody and Recombinant Protein CDMO was valued at $ million in 2024 and will reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Europe market for Antibody and Recombinant Protein CDMO was valued at $ million in 2024 and will reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The global key companies of Antibody and Recombinant Protein CDMO include Batavia Biosciences, Grifols, Cerbios-Pharma SA, HALIX, Biovian Oy, Catalent, Goodwin Biotechnology, Merck, Hangzhou Hs-biopharm, Wuxibiologics, etc. In 2024, the global five largest players hold a share approximately % in terms of revenue.
This report aims to provide a comprehensive presentation of the global market for Antibody and Recombinant Protein CDMO, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Antibody and Recombinant Protein CDMO by region & country, by Type, and by Application.
The Antibody and Recombinant Protein CDMO market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Antibody and Recombinant Protein CDMO.
MARKET SEGMENTATION
By Company
- Batavia Biosciences
- Grifols
- Cerbios-Pharma SA
- HALIX
- Biovian Oy
- Catalent
- Goodwin Biotechnology
- Merck
- Hangzhou Hs-biopharm
- Wuxibiologics
- Bioinnobio
- Thousand Oaks Biopharmaceuticals
- Eurogentec
- HJB
- Bibo Pharma
- MabPlex International
- Genscriptprobio
- Vetter
- Etinpro (Beijing) Co
- Boehringer Ingelheim BioXcellence
- Lonza
- 3SBio Inc
- Porton
Consumption by Region
- North America
- United States
- Canada
- Asia-Pacific
- China
- Japan
- South Korea
- Southeast Asia
- India
- Australia
- Rest of Asia-Pacific
- Europe
- Germany
- France
- U.K.
- Italy
- Netherlands
- Nordic Countries
- Rest of Europe
- Latin America
- Mexico
- Brazil
- Rest of Latin America
- Middle East & Africa
- Turkey
- Saudi Arabia
- UAE
- Rest of MEA
Segment by Type
- Antibody CDMO
- Recombinant Protein CDMO
Segment by Application
- Pharmaceutical Company
- Biotechnology Company
- Generic Company
CHAPTER OUTLINE
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Antibody and Recombinant Protein CDMO company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Antibody and Recombinant Protein CDMO in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Antibody and Recombinant Protein CDMO in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
QYRESEARCH'S STRENGTHS
Unlike generic global market reports, this study combines macro-level industry trends with hyper-local operational intelligence, empowering data-driven decisions across the Compound Chocolate value chain, addressing:
We identify regional market threats and growth prospects to guide your overseas layout.
We adjust product portfolios in line with local consumption habits.
We unpack rivals’ operation strategies for scattered and highly concentrated industries.
We cover competition landscape, full supply chain and quantified market size data, and deliver tailor-made customized surveys to meet your unique business demands.
We own self-owned massive exclusive databases, backed by 19 years of global market research experience across thousands of sectors.
Our team operates 24 hours a day, 365 days a year, enabling ultra-fast report turnaround to respond to your research needs efficiently.
We integrate regional risk assessment, localized product optimization and competitor analysis to deliver actionable market strategies.
All data is cross-verified from multiple industry sources to deliver thorough, precise analysis that supports reliable corporate strategic decisions.
We provide responsive, dedicated after-sales support to resolve all follow-up inquiries about reports, data and industry interpretation.
TABLE OF CONTENTS
1 Market Overview
1.1 Antibody and Recombinant Protein CDMO Product Introduction
1.2 Global Antibody and Recombinant Protein CDMO Market Size Forecast (2020-2031)
1.3 Antibody and Recombinant Protein CDMO Market Trends & Drivers
1.3.1 Antibody and Recombinant Protein CDMO Industry Trends
1.3.2 Antibody and Recombinant Protein CDMO Market Drivers & Opportunity
1.3.3 Antibody and Recombinant Protein CDMO Market Challenges
1.3.4 Antibody and Recombinant Protein CDMO Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Antibody and Recombinant Protein CDMO Players Revenue Ranking (2024)
2.2 Global Antibody and Recombinant Protein CDMO Revenue by Company (2020-2025)
2.3 Key Companies Antibody and Recombinant Protein CDMO Manufacturing Base Distribution and Headquarters
2.4 Key Companies Antibody and Recombinant Protein CDMO Product Offered
2.5 Key Companies Time to Begin Mass Production of Antibody and Recombinant Protein CDMO
2.6 Antibody and Recombinant Protein CDMO Market Competitive Analysis
2.6.1 Antibody and Recombinant Protein CDMO Market Concentration Rate (2020-2025)
2.6.2 Global 5 and 10 Largest Companies by Antibody and Recombinant Protein CDMO Revenue in 2024
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Antibody and Recombinant Protein CDMO as of 2024)
2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Antibody CDMO
3.1.2 Recombinant Protein CDMO
3.2 Global Antibody and Recombinant Protein CDMO Sales Value by Type
3.2.1 Global Antibody and Recombinant Protein CDMO Sales Value by Type (2020 VS 2024 VS 2031)
3.2.2 Global Antibody and Recombinant Protein CDMO Sales Value, by Type (2020-2031)
3.2.3 Global Antibody and Recombinant Protein CDMO Sales Value, by Type (%) (2020-2031)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Pharmaceutical Company
4.1.2 Biotechnology Company
4.1.3 Generic Company
4.2 Global Antibody and Recombinant Protein CDMO Sales Value by Application
4.2.1 Global Antibody and Recombinant Protein CDMO Sales Value by Application (2020 VS 2024 VS 2031)
4.2.2 Global Antibody and Recombinant Protein CDMO Sales Value, by Application (2020-2031)
4.2.3 Global Antibody and Recombinant Protein CDMO Sales Value, by Application (%) (2020-2031)
5 Segmentation by Region
5.1 Global Antibody and Recombinant Protein CDMO Sales Value by Region
5.1.1 Global Antibody and Recombinant Protein CDMO Sales Value by Region: 2020 VS 2024 VS 2031
5.1.2 Global Antibody and Recombinant Protein CDMO Sales Value by Region (2020-2025)
5.1.3 Global Antibody and Recombinant Protein CDMO Sales Value by Region (2026-2031)
5.1.4 Global Antibody and Recombinant Protein CDMO Sales Value by Region (%), (2020-2031)
5.2 North America
5.2.1 North America Antibody and Recombinant Protein CDMO Sales Value, 2020-2031
5.2.2 North America Antibody and Recombinant Protein CDMO Sales Value by Country (%), 2024 VS 2031
5.3 Europe
5.3.1 Europe Antibody and Recombinant Protein CDMO Sales Value, 2020-2031
5.3.2 Europe Antibody and Recombinant Protein CDMO Sales Value by Country (%), 2024 VS 2031
5.4 Asia Pacific
5.4.1 Asia Pacific Antibody and Recombinant Protein CDMO Sales Value, 2020-2031
5.4.2 Asia Pacific Antibody and Recombinant Protein CDMO Sales Value by Region (%), 2024 VS 2031
5.5 South America
5.5.1 South America Antibody and Recombinant Protein CDMO Sales Value, 2020-2031
5.5.2 South America Antibody and Recombinant Protein CDMO Sales Value by Country (%), 2024 VS 2031
5.6 Middle East & Africa
5.6.1 Middle East & Africa Antibody and Recombinant Protein CDMO Sales Value, 2020-2031
5.6.2 Middle East & Africa Antibody and Recombinant Protein CDMO Sales Value by Country (%), 2024 VS 2031
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Antibody and Recombinant Protein CDMO Sales Value Growth Trends, 2020 VS 2024 VS 2031
6.2 Key Countries/Regions Antibody and Recombinant Protein CDMO Sales Value, 2020-2031
6.3 United States
6.3.1 United States Antibody and Recombinant Protein CDMO Sales Value, 2020-2031
6.3.2 United States Antibody and Recombinant Protein CDMO Sales Value by Type (%), 2024 VS 2031
6.3.3 United States Antibody and Recombinant Protein CDMO Sales Value by Application, 2024 VS 2031
6.4 Europe
6.4.1 Europe Antibody and Recombinant Protein CDMO Sales Value, 2020-2031
6.4.2 Europe Antibody and Recombinant Protein CDMO Sales Value by Type (%), 2024 VS 2031
6.4.3 Europe Antibody and Recombinant Protein CDMO Sales Value by Application, 2024 VS 2031
6.5 China
6.5.1 China Antibody and Recombinant Protein CDMO Sales Value, 2020-2031
6.5.2 China Antibody and Recombinant Protein CDMO Sales Value by Type (%), 2024 VS 2031
6.5.3 China Antibody and Recombinant Protein CDMO Sales Value by Application, 2024 VS 2031
6.6 Japan
6.6.1 Japan Antibody and Recombinant Protein CDMO Sales Value, 2020-2031
6.6.2 Japan Antibody and Recombinant Protein CDMO Sales Value by Type (%), 2024 VS 2031
6.6.3 Japan Antibody and Recombinant Protein CDMO Sales Value by Application, 2024 VS 2031
6.7 South Korea
6.7.1 South Korea Antibody and Recombinant Protein CDMO Sales Value, 2020-2031
6.7.2 South Korea Antibody and Recombinant Protein CDMO Sales Value by Type (%), 2024 VS 2031
6.7.3 South Korea Antibody and Recombinant Protein CDMO Sales Value by Application, 2024 VS 2031
6.8 Southeast Asia
6.8.1 Southeast Asia Antibody and Recombinant Protein CDMO Sales Value, 2020-2031
6.8.2 Southeast Asia Antibody and Recombinant Protein CDMO Sales Value by Type (%), 2024 VS 2031
6.8.3 Southeast Asia Antibody and Recombinant Protein CDMO Sales Value by Application, 2024 VS 2031
6.9 India
6.9.1 India Antibody and Recombinant Protein CDMO Sales Value, 2020-2031
6.9.2 India Antibody and Recombinant Protein CDMO Sales Value by Type (%), 2024 VS 2031
6.9.3 India Antibody and Recombinant Protein CDMO Sales Value by Application, 2024 VS 2031
7 Company Profiles
7.1 Batavia Biosciences
7.1.1 Batavia Biosciences Profile
7.1.2 Batavia Biosciences Main Business
7.1.3 Batavia Biosciences Antibody and Recombinant Protein CDMO Products, Services and Solutions
7.1.4 Batavia Biosciences Antibody and Recombinant Protein CDMO Revenue (US$ Million) & (2020-2025)
7.1.5 Batavia Biosciences Recent Developments
7.2 Grifols
7.2.1 Grifols Profile
7.2.2 Grifols Main Business
7.2.3 Grifols Antibody and Recombinant Protein CDMO Products, Services and Solutions
7.2.4 Grifols Antibody and Recombinant Protein CDMO Revenue (US$ Million) & (2020-2025)
7.2.5 Grifols Recent Developments
7.3 Cerbios-Pharma SA
7.3.1 Cerbios-Pharma SA Profile
7.3.2 Cerbios-Pharma SA Main Business
7.3.3 Cerbios-Pharma SA Antibody and Recombinant Protein CDMO Products, Services and Solutions
7.3.4 Cerbios-Pharma SA Antibody and Recombinant Protein CDMO Revenue (US$ Million) & (2020-2025)
7.3.5 Cerbios-Pharma SA Recent Developments
7.4 HALIX
7.4.1 HALIX Profile
7.4.2 HALIX Main Business
7.4.3 HALIX Antibody and Recombinant Protein CDMO Products, Services and Solutions
7.4.4 HALIX Antibody and Recombinant Protein CDMO Revenue (US$ Million) & (2020-2025)
7.4.5 HALIX Recent Developments
7.5 Biovian Oy
7.5.1 Biovian Oy Profile
7.5.2 Biovian Oy Main Business
7.5.3 Biovian Oy Antibody and Recombinant Protein CDMO Products, Services and Solutions
7.5.4 Biovian Oy Antibody and Recombinant Protein CDMO Revenue (US$ Million) & (2020-2025)
7.5.5 Biovian Oy Recent Developments
7.6 Catalent
7.6.1 Catalent Profile
7.6.2 Catalent Main Business
7.6.3 Catalent Antibody and Recombinant Protein CDMO Products, Services and Solutions
7.6.4 Catalent Antibody and Recombinant Protein CDMO Revenue (US$ Million) & (2020-2025)
7.6.5 Catalent Recent Developments
7.7 Goodwin Biotechnology
7.7.1 Goodwin Biotechnology Profile
7.7.2 Goodwin Biotechnology Main Business
7.7.3 Goodwin Biotechnology Antibody and Recombinant Protein CDMO Products, Services and Solutions
7.7.4 Goodwin Biotechnology Antibody and Recombinant Protein CDMO Revenue (US$ Million) & (2020-2025)
7.7.5 Goodwin Biotechnology Recent Developments
7.8 Merck
7.8.1 Merck Profile
7.8.2 Merck Main Business
7.8.3 Merck Antibody and Recombinant Protein CDMO Products, Services and Solutions
7.8.4 Merck Antibody and Recombinant Protein CDMO Revenue (US$ Million) & (2020-2025)
7.8.5 Merck Recent Developments
7.9 Hangzhou Hs-biopharm
7.9.1 Hangzhou Hs-biopharm Profile
7.9.2 Hangzhou Hs-biopharm Main Business
7.9.3 Hangzhou Hs-biopharm Antibody and Recombinant Protein CDMO Products, Services and Solutions
7.9.4 Hangzhou Hs-biopharm Antibody and Recombinant Protein CDMO Revenue (US$ Million) & (2020-2025)
7.9.5 Hangzhou Hs-biopharm Recent Developments
7.10 Wuxibiologics
7.10.1 Wuxibiologics Profile
7.10.2 Wuxibiologics Main Business
7.10.3 Wuxibiologics Antibody and Recombinant Protein CDMO Products, Services and Solutions
7.10.4 Wuxibiologics Antibody and Recombinant Protein CDMO Revenue (US$ Million) & (2020-2025)
7.10.5 Wuxibiologics Recent Developments
7.11 Bioinnobio
7.11.1 Bioinnobio Profile
7.11.2 Bioinnobio Main Business
7.11.3 Bioinnobio Antibody and Recombinant Protein CDMO Products, Services and Solutions
7.11.4 Bioinnobio Antibody and Recombinant Protein CDMO Revenue (US$ Million) & (2020-2025)
7.11.5 Bioinnobio Recent Developments
7.12 Thousand Oaks Biopharmaceuticals
7.12.1 Thousand Oaks Biopharmaceuticals Profile
7.12.2 Thousand Oaks Biopharmaceuticals Main Business
7.12.3 Thousand Oaks Biopharmaceuticals Antibody and Recombinant Protein CDMO Products, Services and Solutions
7.12.4 Thousand Oaks Biopharmaceuticals Antibody and Recombinant Protein CDMO Revenue (US$ Million) & (2020-2025)
7.12.5 Thousand Oaks Biopharmaceuticals Recent Developments
7.13 Eurogentec
7.13.1 Eurogentec Profile
7.13.2 Eurogentec Main Business
7.13.3 Eurogentec Antibody and Recombinant Protein CDMO Products, Services and Solutions
7.13.4 Eurogentec Antibody and Recombinant Protein CDMO Revenue (US$ Million) & (2020-2025)
7.13.5 Eurogentec Recent Developments
7.14 HJB
7.14.1 HJB Profile
7.14.2 HJB Main Business
7.14.3 HJB Antibody and Recombinant Protein CDMO Products, Services and Solutions
7.14.4 HJB Antibody and Recombinant Protein CDMO Revenue (US$ Million) & (2020-2025)
7.14.5 HJB Recent Developments
7.15 Bibo Pharma
7.15.1 Bibo Pharma Profile
7.15.2 Bibo Pharma Main Business
7.15.3 Bibo Pharma Antibody and Recombinant Protein CDMO Products, Services and Solutions
7.15.4 Bibo Pharma Antibody and Recombinant Protein CDMO Revenue (US$ Million) & (2020-2025)
7.15.5 Bibo Pharma Recent Developments
7.16 MabPlex International
7.16.1 MabPlex International Profile
7.16.2 MabPlex International Main Business
7.16.3 MabPlex International Antibody and Recombinant Protein CDMO Products, Services and Solutions
7.16.4 MabPlex International Antibody and Recombinant Protein CDMO Revenue (US$ Million) & (2020-2025)
7.16.5 MabPlex International Recent Developments
7.17 Genscriptprobio
7.17.1 Genscriptprobio Profile
7.17.2 Genscriptprobio Main Business
7.17.3 Genscriptprobio Antibody and Recombinant Protein CDMO Products, Services and Solutions
7.17.4 Genscriptprobio Antibody and Recombinant Protein CDMO Revenue (US$ Million) & (2020-2025)
7.17.5 Genscriptprobio Recent Developments
7.18 Vetter
7.18.1 Vetter Profile
7.18.2 Vetter Main Business
7.18.3 Vetter Antibody and Recombinant Protein CDMO Products, Services and Solutions
7.18.4 Vetter Antibody and Recombinant Protein CDMO Revenue (US$ Million) & (2020-2025)
7.18.5 Vetter Recent Developments
7.19 Etinpro (Beijing) Co
7.19.1 Etinpro (Beijing) Co Profile
7.19.2 Etinpro (Beijing) Co Main Business
7.19.3 Etinpro (Beijing) Co Antibody and Recombinant Protein CDMO Products, Services and Solutions
7.19.4 Etinpro (Beijing) Co Antibody and Recombinant Protein CDMO Revenue (US$ Million) & (2020-2025)
7.19.5 Etinpro (Beijing) Co Recent Developments
7.20 Boehringer Ingelheim BioXcellence
7.20.1 Boehringer Ingelheim BioXcellence Profile
7.20.2 Boehringer Ingelheim BioXcellence Main Business
7.20.3 Boehringer Ingelheim BioXcellence Antibody and Recombinant Protein CDMO Products, Services and Solutions
7.20.4 Boehringer Ingelheim BioXcellence Antibody and Recombinant Protein CDMO Revenue (US$ Million) & (2020-2025)
7.20.5 Boehringer Ingelheim BioXcellence Recent Developments
7.21 Lonza
7.21.1 Lonza Profile
7.21.2 Lonza Main Business
7.21.3 Lonza Antibody and Recombinant Protein CDMO Products, Services and Solutions
7.21.4 Lonza Antibody and Recombinant Protein CDMO Revenue (US$ Million) & (2020-2025)
7.21.5 Lonza Recent Developments
7.22 3SBio Inc
7.22.1 3SBio Inc Profile
7.22.2 3SBio Inc Main Business
7.22.3 3SBio Inc Antibody and Recombinant Protein CDMO Products, Services and Solutions
7.22.4 3SBio Inc Antibody and Recombinant Protein CDMO Revenue (US$ Million) & (2020-2025)
7.22.5 3SBio Inc Recent Developments
7.23 Porton
7.23.1 Porton Profile
7.23.2 Porton Main Business
7.23.3 Porton Antibody and Recombinant Protein CDMO Products, Services and Solutions
7.23.4 Porton Antibody and Recombinant Protein CDMO Revenue (US$ Million) & (2020-2025)
7.23.5 Porton Recent Developments
8 Industry Chain Analysis
8.1 Antibody and Recombinant Protein CDMO Industrial Chain
8.2 Antibody and Recombinant Protein CDMO Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Antibody and Recombinant Protein CDMO Sales Model
8.5.2 Sales Channel
8.5.3 Antibody and Recombinant Protein CDMO Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.1.1 Research Programs/Design
10.1.1.2 Market Size Estimation
10.1.1.3 Market Breakdown and Data Triangulation
10.1.2 Data Source
10.1.2.1 Secondary Sources
10.1.2.2 Primary Sources
10.2 Author Details
10.3 Disclaimer
TABLE OF FIGURES
List of Tables
List of Figures
KEY QUESTIONS ADDRESSED BY THE REPORT
Related Reports
Global Antibody and Recombinant Protein CDMO Market Research Report 2025
The global market for Antibody and Recombinant Protein CDMO was valued at US$ 59130 million in the year 2024 and is projected to reach a revised size of US$ 94330 million by 2031, growing at a CAGR of 7.0% during the forecast period.
Published Date: 2025-01-16
Pages: 105
USD 2900.00
(Single User License)
Global Antibody and Recombinant Protein CDMO Market Insights, Forecast to 2030
Market Analysis and Insights: Global Antibody and Recombinant Protein CDMO Market
Published Date: 2024-04-12
Pages: 129
USD 4900.00
(Single User License)
Global Antibody and Recombinant Protein CDMO Market Research Report 2024
The global Antibody and Recombinant Protein CDMO market was valued at US$ 51310 million in 2023 and is anticipated to reach US$ 83480 million by 2030, witnessing a CAGR of 7.0% during the forecast period 2024-2030.
Published Date: 2024-01-12
Pages: 106
USD 2900.00
(Single User License)
Antibody and Recombinant Protein CDMO - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
The global market for Antibody and Recombinant Protein CDMO was estimated to be worth US$ 51310 million in 2023 and is forecast to a readjusted size of US$ 83480 million by 2030 with a CAGR of 7.0% during the forecast period 2024-2030
Published Date: 2024-01-08
Pages: 156
USD 3950.00
(Single User License)
Global Antibody and Recombinant Protein CDMO Market Research Report 2025
The global market for Antibody and Recombinant Protein CDMO was valued at US$ 59130 million in the year 2024 and is projected to reach a revised size of US$ 94330 million by 2031, growing at a CAGR of 7.0% during the forecast period.
Published: 2025-01-16
Pages: 105
USD 2900.00 (Single User License)Global Antibody and Recombinant Protein CDMO Market Insights, Forecast to 2030
Market Analysis and Insights: Global Antibody and Recombinant Protein CDMO Market
Published: 2024-04-12
Pages: 129
USD 4900.00 (Single User License)Global Antibody and Recombinant Protein CDMO Market Research Report 2024
The global Antibody and Recombinant Protein CDMO market was valued at US$ 51310 million in 2023 and is anticipated to reach US$ 83480 million by 2030, witnessing a CAGR of 7.0% during the forecast period 2024-2030.
Published: 2024-01-12
Pages: 106
USD 2900.00 (Single User License)Antibody and Recombinant Protein CDMO - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
The global market for Antibody and Recombinant Protein CDMO was estimated to be worth US$ 51310 million in 2023 and is forecast to a readjusted size of US$ 83480 million by 2030 with a CAGR of 7.0% during the forecast period 2024-2030
Published: 2024-01-08
Pages: 156
USD 3950.00 (Single User License)
USD 3950.00
USD 5925.00
USD 7900.00
Add to Cart
Buy Now
REPORT COVERAGE
DESCRIPTION
OVERVIEW
MARKET SEGMENTATION
CHAPTER OUTLINE
QYRESEARCH'S STRENGTHS
TABLE OF CONTENTS
TABLE OF FIGURES
RLEATED REPORTS
INTEREST IN THIS REPORT?
Get A Free Sample
Request For Quotation
OR
NEED A CUSTOMIZED REPORT?
Customized Report
Request Sample
Pre-Order Enquiry
Add to Cart
Buy Now